top of page

Syntis Bio reports SYNTIETY-1 outcomes demonstrating SYNT-101 mimics gastric bypass hormone response with placebo-like tolerability

7 minutes ago
2 min read

Syntis Bio has announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-driven gut-hormone response of gastric bypass surgery, produced placebo-adjusted weight loss over 28 days, and was well tolerated, with gastrointestinal (GI) adverse events comparable to placebo and no discontinuations.


As reported in July and September 2026, SYNT-101 was well tolerated across both the single ascending dose (SAD) and multiple ascending dose (MAD) portions of the Phase 1/1b SYNTIETY-1 trial, with no discontinuations among 55 dosed participants, and demonstrated nutrient redirection and a multi-hormone satiety response consistent with gastric bypass. The SAD portion enrolled 32 healthy adults; the 28-day MAD portion enrolled 23 adults with obesity.


New data presented at ObesityWeek include:

  • Placebo-adjusted weight change at Day 28 of −1.26%, −0.46% and −2.30% in the 857 mg, 1,714 mg and 2,571 mg cohorts, respectively, and −1.37% pooled (nominal p=0.007).

  • At Day 28, the OGTT response increased 5.1-fold for PYY and 2.3-fold for GLP-1 versus pre-treatment, with 37% suppression of ghrelin and no change in insulin.

  • The highest-dose cohort had both the largest hormone response (PYY 8.7-fold) and the largest weight loss (exploratory, cohort-level).

  • Treatment-related GI adverse events occurred in 35% of SYNT-101 participants versus 33% on placebo, with no dose-response pattern and no treatment-related vomiting.


SYNTIETY-1 was a randomised, double-blind, placebo-controlled Phase 1/1b trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of SYNT-101. The trial comprised two parts: a single ascending dose (SAD) portion, which enrolled 32 adults (BMI 18.5 to 29.9 kg/m²) across four cohorts receiving a single dose of SYNT-101 (857 mg to 3,428 mg, corresponding to one to four tablets) or placebo, and a multiple ascending dose (MAD) portion, which enrolled 23 adults with obesity (BMI 30 to <40 kg/m²) across three cohorts receiving SYNT-101 (857 mg, 1,714 mg or 2,571 mg) or placebo once daily for 28 days.


The primary endpoint was safety and tolerability. Exploratory endpoints included changes in gut-hormone response to an oral glucose tolerance test (OGTT), glucose absorption measured by continuous glucose monitoring, and, in the MAD portion, change in body weight.

 

Syntis plans to initiate a Phase 2 study of SYNT-101 for obesity in 2027.

Comments


Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Get in touch!
Email: info@bariatricnews.net

©2026 Dendrite Clinical Systems Ltd. All rights reserved.
No part of this website may be reproduced, stored in a retrieval system, transmitted in any form or by any other means without prior written permission from the Managing Editor. The views, comments and opinions expressed within are not necessarily those of Dendrite Clinical Systems or the Editorial Board. Bariatricnews.net is a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

bottom of page